HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “SPA”) for the purchase and sale of an aggregate of 610,399 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.36 per share (or pre-funded warrant in lieu thereof) in a registered direct offering... Read More

NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today issued a public statement urging Alaunos Therapeutics, Inc. (NASDAQ: TCRT) to accept and act upon the term sheet previously facilitated through a leading Wall Street Bank. As disclosed in PMGC Capital’s May 14, 2025 press release, available on the PMGC Holdings... Read More

NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (Nasdaq: TCRT). PMGC Capital has acquired 83,500 shares of Alaunos... Read More

TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53 Company... Read More

TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potential partnering opportunities for the hunTR ® platform as well as broad strategic alternatives Reducing headcount by approximately 60% while... Read More

HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Company will present at the 2 nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023. Alaunos Director of Translational Sciences... Read More

TCR-T cell therapy shows first-in-human response for non-viral TCR-T therapy; effectively targets high frequency TP53 and KRAS driver mutations across multiple solid tumor indications Treatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in peripheral blood observed in all three treated patients at last follow-up Proof-of-concept demonstrated for non-viral Sleeping Beauty cell... Read More

Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023 Fully prepaid loan with Silicon Valley Bank; now a debt-free company Amended exclusive licensing agreement with Precigen, Inc., reflecting the Company’s focus on its TCR-T programs and eliminating long-term financial obligations Company to host conference call... Read More

HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the... Read More

HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced a poster presentation for its lead non-viral Sleeping Beauty TCR-T cell therapy program in solid tumors at the 2023 American Society of Clinical Oncology (ASCO) Annual... Read More

HOUSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced the appointment of Robert J. Hofmeister, PhD, MS, Chief Scientific Officer of a stealth early stage biotechnology company, to the Company’s Board of Directors, effective... Read More

HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences. Cantor's The Future of Oncology Virtual Symposium Date: Tuesday, April 4, 2023... Read More

Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvironment; provides support for next generation TCR-T efforts Advancing TCR-T Library Program towards Phase 2 readiness with accelerated patient enrollment following proof-of-concept of Sleeping Beauty TCR-T in solid tumors targeting driver mutations Expanded TCR library with two new TCRs;... Read More

HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, on Tuesday, March 7, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast... Read More

Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platform Increasing patient enrollment to advance TCR-T Library Program towards Phase 2 using high value TCRs targeting common hotspot mutations in six solid tumor indications Executing against multi-pronged strategy to expand and optimize manufacturing capabilities... Read More